Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- TB & COVID-19 in the media
- Outline
- Similarities & differences
- Other similarities & differences
- What was known before GTN studies?
- Study 1 of 49 cases
- Study 1 of 49 cases: generalities
- Study 1 of 49 cases: history of TB
- Study 1 of 49 cases: other variables
- Study 1 of 49 cases: COVID-19
- Conclusions from study 1
- Study 2 of 20 cases (1)
- Study 2 of 20 cases (2)
- Conclusions from study 2
- Preliminary research questions
- Study 3 of 69 cases (mortality)
- Conclusions from study 3
- Study 4: Clinical Infectious Diseases (CID) 2020
- Study 5: TB & COVID-19 in the Philippines
- Does BCG protect against COVID-19?
- GTN study: evidence on BCG vaccination
- GTN study: updated evidence
- Description of TB/COVID-19 patients
- Signs & symptoms
- Radiology
- Treatment
- Outcomes
- Evidence for research questions 1 & 2
- Central Reference MDR-TB Centre
- Impact on TB services in Sierra Leone & Italy
- GTN study: impact on health systems
- Diagnosis of active TB: Asia-Pacific region
- Diagnosis of active TB: the Americas
- Diagnosis of active TB: Africa
- Diagnosis of active TB: Russia
- Diagnosis of LTBI: the Americas
- Diagnosis of LTBI: Sierra Leone & Russia
- Diagnosis of TB: Singapore
- Impact of COVID-19 on (L)TBI management
- Global tuberculosis report 2020 (1)
- Global tuberculosis report 2020 (2)
- We warmly thank all contributors
- Q & A: TB/COVID-19
- Conclusions
- Should we fear the 'cursed duet'?
- Conflict of interest
Topics Covered
- Similarities and differences between TB and COVID-19
- Evidence of COVID-19 and TB co-infection
- Impact of co-infection on mortality
- Research priorities and global GTN study results
- BCG vaccine protection & COVID-19
- Impact of COVID-19 on health services
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Migliori, G.B. (2021, September 29). Tuberculosis and COVID-19 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/MCXF3606.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Giovanni Battista Migliori has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Respiratory Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I am Professor Giovanni Battista Migliori,
Director of the WHO Collaborating Center for TB and Lung Diseases at Maugeri Institute, Tradate, Italy,
honorary professor at Queen Mary University in London, and chair of the GTN,
the Global Tuberculosis Network.
Today we are going to speak about tuberculosis and COVID-19.
0:24
We can see here that the media, as well as newspapers,
quite often cover the issue of TB and Covid,
and at one time the number of presentations/articles on TB and Covid - particularly on Covid -
were overwhelming, following the first wave of the COVID-19 pandemic.
But both in the scientific literature and the mainstream media, it seems that the bigger monster
is Covid, and that the main possible victim of the interaction will be TB (as we will see),
because of the problems that TB services have faced as a result of COVID-19.
1:09
This is the summary of the presentation.
We will briefly revise similarities and differences between COVID-19 and TB.
We will revise what the preliminary evidence on the two infections was,
before the studies of the Global Tuberculosis Network.
We will then describe the main contribution that was made by the GTN with its first studies.
We'll discuss mortality, the protection that BCG (the present vaccine for TB)
might eventually provide to protect people from COVID-19.
We will discuss the impact on health systems, to draw some conclusions at the end.